What is Udenafil? Udenafil is a selective, orally administered phosphodiesterase type 5 (PDE5) inhibitor developed for the treatment of erectile dysfunction (ED). Approved in several Asian and European countries under the brand name Zydena, it occupies a unique position in the ED treatment landscape due to its intermediate pharmacokinetic profile, which combines a rapid onset of action with a duration of effect lasting up to 24 hours. Udenafil is used as an on-demand medication or as a low-dose daily regimen, providing flexibility and convenience for patients. Its high selectivity for the PDE5 enzyme helps minimize some of the common side effects associated with other PDE5 inhibitors. Mechanism of Action Penile erection is a hemodynamic process initiated by the release of nitric oxide (NO) in the corpus cavernosum during sexual stimulation. Nitric oxide activates guanylate cyclase, which increases levels of cyclic guanosine monophosphate (cGMP). cGMP acts as a second messenger, causing smooth muscle relaxation in the corpus cavernosum and penile arterioles. This vasodilation allows blood to flow into the erectile tissue, producing an erection. The enzyme phosphodiesterase type 5 (PDE5) is responsible for breaking down cGMP, returning the penis to a flaccid state. Udenafil is a potent and highly selective inhibitor of the PDE5 enzyme. By blocking PDE5, Udenafil prevents the degradation of cGMP in the corpus cavernosum, prolonging the vasodilatory effects of nitric oxide. When sexual stimulation causes local nitric oxide release, Udenafil’s inhibition of PDE5 leads to increased levels of cGMP, facilitating smooth muscle relaxation and blood inflow to produce a firm erection. Udenafil has no direct relaxant effect on the corpus cavernosum and requires sexual stimulation to work. Pharmacokinetics & Intermediate Duration Udenafil is rapidly absorbed after oral administration, with peak plasma concentrations (Cmax) achieved within 1 to 1.5 hours (Tmax). It has a high absolute bioavailability. Udenafil can be taken with or without food, although a high-fat meal can delay absorption. It is highly bound to plasma proteins (approximately 94%) and is widely distributed in body tissues. Udenafil is metabolized in the liver primarily by the cytochrome P450 CYP3A4 enzyme. The elimination half-life of Udenafil is approximately 11 to 13 hours. This intermediate half-life is a key clinical differentiator: it is longer than that of Sildenafil (4 hours) and Vardenafil (4-5 hours), but shorter than Tadalafil (17.5 hours). This provides a therapeutic window of up to 12 to 24 hours, allowing for spontaneity without the prolonged drug exposure of longer-acting agents. Elimination occurs primarily through feces (as metabolites) and to a lesser extent through urine. Clinical Indications & Dosage Udenafil is indicated for the treatment of erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance. The standard recommended starting dose is 100 mg taken orally, with or without food, approximately 30 minutes to 1 hour before anticipated sexual activity. Based on individual efficacy and tolerability, the dose may be increased to 200 mg. The maximum recommended dosing frequency is once daily. For daily-use therapy, a lower dose of 50 mg or 75 mg taken at the same time each day is prescribed, allowing for erections at any time in response to sexual arousal. Warnings & Safety Warnings Udenafil shares the safety contraindications and warnings typical of the PDE5 inhibitor class: Nitrates Contraindication: Consistent with its mechanism of action, Udenafil potentiates the hypotensive effects of nitrates. Co-administration of Udenafil with organic nitrates or nitric oxide donors (such as nitroglycerin or amyl nitrite) in any form is strictly contraindicated due to the risk of severe, life-threatening hypotension. Cardiovascular Status: Sexual activity carries a potential cardiac risk. Patients with severe cardiovascular disease—including recent myocardial infarction or stroke (within 6 months), unstable angina, uncontrolled hypertension, or severe arrhythmias—should not use Udenafil. Selectivity Profile: Udenafil exhibits high selectivity for PDE5 over other phosphodiesterases. It has low cross-reactivity with PDE6 (found in the retina) and PDE11 (found in skeletal muscle and testes), which reduces the incidence of visual disturbances and muscle pain (myalgia) compared to some other ED drugs. Frequently Asked Questions How long does Udenafil last? Udenafil has a duration of action of approximately 12 to 24 hours. This intermediate duration allows men to achieve erections within this timeframe in response to sexual stimulation, providing a balance between short-acting and long-acting ED treatments. Are there any visual side effects with Udenafil? Visual side effects (such as blue-tinged vision) are extremely rare with Udenafil due to its high selectivity for the PDE5 enzyme over the PDE6 enzyme found in the retina. This makes it a preferred option for patients sensitive to visual changes from other ED medications.